Immunomodulatory effect of IL-2 induced bone marrow mononuclear cell therapy on control of allergic asthma

• Published in: Allergologia et immunopathologia 2023, Vol.51 (1), p.110-115
• Main Authors: Yin, Jingjing, Yan, Fengdi, Zheng, Ruiqiang, Wu, Xiaoyan, Athari, Seyyed Shamsadin
• Format: Article
• Language: English
• Subjects: Airway management; Animals; Asthma; Asthma - pathology; Bone Marrow; Bronchoalveolar Lavage Fluid; Cell growth; Cytokines; Cytokines - metabolism; Disease; Disease Models, Animal; Growth factors; Histopathology; Hyperplasia; Hypersensitivity - pathology; Inflammation; Inflammation - pathology; Interleukin-13; Interleukin-2 - pharmacology; Leukocytes, Mononuclear; Lung - pathology; Lymphocytes; Mice; Mice, Inbred BALB C; Ovalbumin; Transforming Growth Factor beta
• ISSN: 0301-0546; 1578-1267; 0301-0546
• DOI: 10.15586/aei.v51i1.746

Asthma is a chronic airway disease. Allergic reactions and T helper (h)2 immune response play a key role in asthma occurrence. Cell therapy can control inflammation and remodeling responses in allergic asthma, and cytokines can change this effect. Therefore, in this study, the effect of treated cell therapy with IL-2 to control allergic asthma was studied. Bone marrow cells were extracted and co-cultured with IL-2 and the cells were used via intra-tracheal administration in allergic asthma mice. Levels of IL-4, IL-5, IL-13, Leukotriene B4 and C4, and remodeling factors were measured. At least, a histopathology test of lung tissue was done. Type2 cytokines, leukotrienes, remodeling factors, mucus secretion, goblet cell hyperplasia, peri-bronchial and peri-vascular inflammation were significantly (p˂0.05) decreased by treating with bone marrow-derived mononuclear cells (BMDMCs) and IL-2-BMDMCs. Treatment with IL-2-BMDMCs could significantly decrease IL-13, transforming growth factor (TGF)-β, HP levels, and mucus secretion (p˂0.05) compared to BMDMCs treatment. In this study, BMDMCs and IL-2-BMDMCs therapy could decrease inflammation, allergic, and remodeling factors in allergic asthma. Cell therapy with BMDMCs had a strong and notable effect on the control of allergic asthma pathophysiology when co-cultured and used with IL-2.